THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

Arbutus Biopharma Corporation

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERABUS

CORENasdaq-listed company

WATCHEarnings + filings + operating news

STATUSContinuously updated

LIVE / ABUS COVERAGE

What’s moving Arbutus Biopharma Corporation now

Current reporting with the operating signal separated from the noise.

Arbutus Biopharma Corporation: Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction" Tender Offer

Investors are testing whether Arbutus Biopharma Corporation’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

The story matters when it changes Arbutus Biopharma Corporation’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.

Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

The story matters when it changes Arbutus Biopharma Corporation’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.

Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results

The story matters when it changes Arbutus Biopharma Corporation’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.

Arbutus Biopharma Corporation

The story matters when it changes Arbutus Biopharma Corporation’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.

PRIMARY DOCUMENTS / SEC EDGAR

Latest ABUS filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-12 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-23 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-21 · Period 2026-08-21SEC ↗8-KMaterial company eventFiled 2026-08-12 · Period 2026-08-12SEC ↗8-KMaterial company eventFiled 2026-07-16 · Period 2026-07-15SEC ↗6-KOfficial SEC filingFiled 2014-03-21 · Period 2014-03-20SEC ↗6-KOfficial SEC filingFiled 2014-03-18 · Period 2014-03-18SEC ↗

EARNINGS / QUARTERLY TRACKER